comparemela.com
  1. Home
  2. Live Updates
  3. Ncluding Rptx Us7602731025 - Breaking News

Latest Breaking News On - Ncluding rptx us7602731025 - Page 1 : comparemela.com

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed. | June 7, 2023

Maria koehlerLloydm segalCompany nasdaqRepare therapeutics incPrincess margaret cancer centerCompany virtual webcast eventCanadian cancer trials groupRepare therapeuticsChief medical officerChief executive officerInitial findingsVirtual webcast eventRepare therapeutics inc stock exchangePress releaseNcluding rptx us7602731025

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.